Myriad Genetics Inc (MYGN)

Return on assets (ROA)

Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019
Net income (ttm) US$ in thousands -116,000 -155,200 -234,600 -263,300 -274,400 -248,200 -146,200 -112,000 -77,300 -17,600 -8,200 -27,200 -34,800 -114,800 -225,300 -194,100 -199,500 -148,300 -26,200 -15,300
Total assets US$ in thousands 1,081,300 1,085,100 1,110,500 1,146,500 1,149,100 1,187,200 1,169,300 1,198,700 1,212,000 1,210,200 1,255,400 1,320,700 1,335,900 1,360,300 1,336,900 1,444,500 1,404,600 1,446,700 1,578,300 1,591,200
ROA -10.73% -14.30% -21.13% -22.97% -23.88% -20.91% -12.50% -9.34% -6.38% -1.45% -0.65% -2.06% -2.60% -8.44% -16.85% -13.44% -14.20% -10.25% -1.66% -0.96%

September 30, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $-116,000K ÷ $1,081,300K
= -10.73%

The return on assets (ROA) of Myriad Genetics Inc has been fluctuating over the past few quarters. ROA measures how efficiently a company can generate profits from its assets, and a negative ROA indicates that the company is not profitable based on its asset base.

Myriad Genetics Inc has experienced negative ROA figures ranging from -22.97% to -0.65% in the past eight quarters. This signifies that the company has been struggling to generate profits relative to its asset base during these periods.

The downward trend in ROA indicates that Myriad Genetics Inc may be facing challenges in effectively utilizing its assets to generate positive returns. Investors and stakeholders should closely monitor the company's efforts to improve its operational efficiency and profitability in order to enhance its ROA.


Peer comparison

Sep 30, 2024